Pre-Made Ensovibep biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting Severe?acute?respiratory syndrome?coronavirus?2 RBD for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ensovibep biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting Severe?acute?respiratory syndrome?coronavirus?2 RBD is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ensovibep is a DARPin therapeutic candidate, designed specifically to inhibit target cell entry of SARS-CoV-2, the virus that causes COVID-19. DARPins (Designed Ankyrin Repeat Proteins) are mono or multi-specific protein-based therapies, designed to specifically engage their targets for various effects. Ensovibep includes three covalently linked individual DARPin domains which bind to the spike protein of SARS-CoV-2. With these domains incorporated into a single molecule, ensovibep is designed to block the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, even in the presence of some mutations of the spike protein. Several characteristics of DARPin therapeutics make them potentially suitable for COVID-19 treatment, including multi-specific binding, the rapid onset of action, and scalable bacterial production.
| Products Name (INN Index) | Pre-Made Ensovibep biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting Severe?acute?respiratory syndrome?coronavirus?2 RBD |
|---|---|
| INN Name | ensovibep |
| Target | Severe?acute?respiratory syndrome?coronavirus?2 RBD |
| Format | Recombinant Protein |
| Derivation | synthetic construct |
| Species Reactivity | Human |
| CH1 Isotype | Alternative to antigen receptors (domain scaffold: ANK, ankyrin repeats) 5 ANK domains |
| VD LC | Alternative to antigen receptors (domain scaffold: ANK, ankyrin repeats) 5 ANK domains |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Molecular?Partners (Switzerland) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | Alternative to antigen receptors, domain?scaffold ANK,?ankyrin repeats (DARPin?) |
| Previous Name | NA |
| Gm Offical Target Name | Severe?acute?respiratory syndrome?coronavirus?2 RBD |
| Package |
